Baird Reiterates Buy Rating on REGENXBIO Inc. with $32 Target
Baird's analyst maintains a bullish stance on REGENXBIO Inc., setting a price target of $32, a 220.96% upside from the current price.
Key Points
- On June 22, 2026, Baird reiterated its buy rating on REGENXBIO Inc. with a price target of $32.
- Baird's $32 price target implies 220.96% upside from REGENXBIO Inc.'s ($RGNX) current $9.97 share price.
- Shares of NasdaqGS:RGNX traded at $7.80 on Tuesday, with a 52-week range of $5.46 to $16.19.
- Insiders made significant purchases in late May, and several analysts maintain a buy rating.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 22, 2026, Baird reiterated its buy rating on REGENXBIO Inc. (NasdaqGS:RGNX), setting a price target of $32. The analyst, Brian Skorney, continues to express confidence in the biotechnology company's prospects.
Baird vs. the S&P 500
Hypothetical, simulated performance of disclosed positions vs. the S&P 500. Not realized profit and not investment advice. Past performance does not indicate future results. Details.
Other Institutional Activity in REGENXBIO Inc.
In recent institutional activity, BlackRock, Inc. grew its holdings by 25,997 shares, ending with 5,782,808 shares worth about $48.5 million. State Street Corp increased its position by 444,749 shares, bringing its total to 2,731,485 shares valued at approximately $22.9 million. Meanwhile, JPMorgan Chase & Co reduced its stake by 69,702 shares, now holding 3,483,800 shares worth $27.1 million. Morgan Stanley added 51,369 shares, resulting in a total of 2,066,157 shares valued at $17.3 million. Vanguard Capital Management LLC opened a new position with 2,007,146 shares, valued at around $16.8 million.
REGENXBIO Inc. Stock Up 3.2%
Shares of NasdaqGS:RGNX traded near $7.80 on Tuesday. REGENXBIO Inc. has a market cap of approximately $468.9 million and a forward P/E ratio that is not meaningful as the company is not currently profitable. The stock's 52-week low is $5.46, and its high is $16.19. The 50-day moving average is $7.95, while the 200-day moving average is $10.34. The company maintains a current ratio of 2.62 and a quick ratio of 2.45, with a high debt-to-equity ratio of 1178.24.
$RGNX price target
Past daily closes and this analyst's 12-month price target. Not investment advice.
Recent Earnings
REGENXBIO Inc. reported revenue of $87.8 million, although it experienced a decline of 92.8% in revenue growth. The company recorded a negative return on equity of -196.43% and a net margin of 0.0%. The next earnings report is expected on August 6, 2026.
Insider Buying and Selling at REGENXBIO Inc.
Several insiders made significant stock purchases on May 29, 2026. Daniel Tasse, Kenneth Mills, David Stump, Allan Fox, and Alexandra Glucksmann each acquired 46,600 shares, while Kenneth Mills and Allan Fox also purchased an additional 9,807 shares. These transactions were not planned under Rule 10b5-1.
Analysts Set New Price Targets
On June 22, 2026, Baird maintained its buy rating for REGENXBIO Inc. with a $32 price target. Leerink Partners also maintained a buy rating, setting a target of $18. Earlier in June, HC Wainwright & Co. reiterated a buy rating with a $26 target. The consensus among analysts is a "buy" rating with an average target price of $23.82, based on opinions from 11 analysts.
About REGENXBIO Inc.
REGENXBIO Inc. is a biotechnology company based in Rockville, Maryland. It focuses on developing gene therapies for treating genetic disorders. The company's NAV Technology Platform is a proprietary system used to deliver functional genes to cells. REGENXBIO is working on several gene therapy candidates, including treatments for retinal diseases and muscular dystrophy. The company collaborates with other biotech firms and has partnerships with AbbVie Global Enterprises and Nippon Shinyaku.
Bottom Line
Baird's reiterated buy rating and $32 price target for REGENXBIO Inc. highlight continued confidence in its potential. The stock's current trading price and recent insider buying activity may interest investors. However, it's important to remember that analyst ratings are based on past data and do not guarantee future performance.
Get REGENXBIO Inc. alerts
New 13F filings, insider trades, and analyst moves on $RGNX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.